Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia® in the US
. Zykadia® (ceritinib) is an approved treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose…
. Zykadia® (ceritinib) is an approved treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose…
There's no doubt about it: regular exercise is good for your health and naturally also for your back. After all, a lack…
Backache is often associated with high levels of suffering and usually has a major impact on the daily life of those aff…
The older we get, the less active our daily lives become, as a rule. After spending our childhood sat at the school desk…
Antisense Pharma GmbH, a biopharmaceutical company headquartered in Germany, has announced the granting of patents for a…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced preliminary data from two studies, Coptimize and Qual…
. - Early Initiation of Treatment with Copaxone® Reduced the Risk of Developing MS by 41 Percent - Copaxone® Delayed T…
. - Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that several new studies supporting the company's inn…
. - More than 80 percent of patients were able to walk unassisted following 15 years of treatment and average disease d…